Showing 1,921 - 1,940 results of 13,613 for search '(( significant ((part decrease) OR (point decrease)) ) OR ( significant increase decrease ))', query time: 0.54s Refine Results
  1. 1921
  2. 1922
  3. 1923
  4. 1924
  5. 1925
  6. 1926
  7. 1927
  8. 1928
  9. 1929
  10. 1930
  11. 1931
  12. 1932
  13. 1933
  14. 1934
  15. 1935
  16. 1936

    CHAMPS pilot Hb dataset. by Jeanie du Toit (20721918)

    Published 2025
    “…Postmortem testing showed a significant decrease in hemoglobin concentrations compared to antemortem levels. …”
  17. 1937
  18. 1938

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  19. 1939

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  20. 1940

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”